Your Health, We Care
Coadministration of Alpelisib with a strong CYP3A4 inducer decreases alpelisib concentration, which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4.
Coadministration of Alpelisib with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. Avoid the use of BCRP inhibitors in patients treated with Alpelisib. If unable to use alternative drugs, when Alpelisib is used in combination with BCRP inhibitors, closely monitor for increased adverse reactions.
Coadministration of Alpelisib with CYP2C9 substrates (e.g., warfarin) may reduce plasma concentration of these drugs. Closely monitor when Alpelisib is used in combination with CYP2C9 substrates where decreases in the plasma concentration of CYP2C9 substrates may reduce activity of these drugs.
from FDA,2022.11
Apellix is a drug used to treat certain types of breast cancer, and its use, sto···【more】
Release date：2024-12-23Recommended：81
Apellix is a therapeutic drug that targets specific types of breast cancer, and ···【more】
Release date：2024-12-23Recommended：97
Apellix is a drug used to treat specific types of breast cancer, and its use, st···【more】
Release date：2024-12-23Recommended：89
Apelix is a drug for the treatment of specific diseases, and special attention s···【more】
Release date：2024-12-20Recommended：69
Alpelisib is the drug of choice for patients with PIK3CA-mutated breast cancer a···【more】
Release date：2024-08-27Recommended：143
In 2022, Alpelisib received accelerated FDA approval for patients on the PIK3CA-···【more】
Release date：2024-08-27Recommended：113
As the first oral small molecule drug for HR/HER2- and PIK3CA-mutated advanced b···【more】
Release date：2024-08-27Recommended：127
